Status:

ACTIVE_NOT_RECRUITING

Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis

Lead Sponsor:

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Conditions:

Dermatitis, Atopic

Eczema, Atopic

Eligibility:

All Genders

18-75 years

Phase:

PHASE3

Brief Summary

This is a randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of 611 when used in combination with topical corticosteroid (TCS) treatment compared wi...

Eligibility Criteria

Inclusion

  • Male or female adults ages 18 to 75 years old when signing the informed consent.
  • AD (according to Hanifin-Rajka Criteria) that had been present for at least 1 years before the screening visit.
  • Moderate to Severe Atopic Dermatitis.
  • Recent history of inadequate response to treatment with topical medications.

Exclusion

  • Participation in a prior 611 clinical study.
  • Treatment with the following prior to the baseline visit: 1) Systemic corticosteroid or Immunosuppressants / Immunomodulators within 4 weeks or within 5 half-lives (if known), whichever is longer. 2) Monoclonal antibody within 5 half-lives (if known) or 4 months, whichever is longer. 3) Cell-depleting within 6 months.
  • Treatment with a live (attenuated) vaccine within 2 months of the baseline visit or planned during the study.
  • Serious or Uncontrolled diseases that may affect the safety of participants during the study period or hinder their completion of the study.
  • Evidence of active acute or chronic hepatitis.
  • History of malignancy within 5 years before the screening visit or currently.
  • Pregnant or breastfeeding women, or women planning to become pregnant.
  • Any history of vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC).

Key Trial Info

Start Date :

September 23 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 16 2026

Estimated Enrollment :

400 Patients enrolled

Trial Details

Trial ID

NCT06554847

Start Date

September 23 2024

End Date

August 16 2026

Last Update

July 14 2025

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Shanghai Dermatology Hospital

Shanghai, Shanghai Municipality, China, 200050

2

Hangzhou First People's Hospital

Hangzhou, Zhejiang, China, 31003

3

The First Affiliated Hospital of Ningbo University

Ningbo, Zhejiang, China, 315010